Activator protein 1 DNA binding activity is decreased in lesional psoriatic skin compared with nonlesional psoriatic skin

Br J Dermatol. 2004 Sep;151(3):600-7. doi: 10.1111/j.1365-2133.2004.06088.x.

Abstract

Background: Psoriasis is a common benign skin disease characterized by hyperproliferation and abnormal differentiation of keratinocytes. The transcription factor activator protein 1 (AP-1) is known to play an important role in cell proliferation and differentiation.

Objectives: To investigate AP-1 DNA binding activity in psoriatic skin.

Methods: Keratome biopsies were taken from patients with plaque-type psoriasis. Electrophoretic mobility shift assays were used to determine the AP-1 DNA binding activity, whereas Western and Northern blotting was used to determine Jun and Fos protein and mRNA expression.

Results: We found that AP-1 DNA binding activity was almost completely abolished in lesional psoriatic skin compared with nonlesional psoriatic skin. Furthermore, experiments revealed that the protein and mRNA expression of the AP-1 subunits c-Fos, Fra-1 and c-Jun was reduced in lesional psoriatic skin compared with nonlesional psoriatic skin, whereas the protein and mRNA expression of the subunit JunB was increased. Topical application of the vitamin D analogue calcipotriol under occlusion to involved psoriatic skin for 4 days resulted in an increase in AP-1 DNA binding activity, and an increase in the protein and mRNA expression of c-Fos, Fra-1 and c-Jun, together with a decrease in JunB protein and mRNA expression.

Conclusions: Together, these results suggest that the activity of the transcription factor AP-1 is impaired in lesional psoriatic skin and that this impairment may be important for the disturbed epidermal growth observed in psoriasis.

MeSH terms

  • Adult
  • Aged
  • Blotting, Northern
  • Blotting, Western
  • Calcitriol / analogs & derivatives*
  • Calcitriol / therapeutic use
  • DNA-Binding Proteins / drug effects
  • DNA-Binding Proteins / metabolism
  • Dermatologic Agents / therapeutic use
  • Electrophoretic Mobility Shift Assay
  • Female
  • Gene Expression Regulation / drug effects
  • Humans
  • Male
  • Middle Aged
  • Proto-Oncogene Proteins c-fos / genetics
  • Proto-Oncogene Proteins c-fos / metabolism
  • Proto-Oncogene Proteins c-jun / genetics
  • Proto-Oncogene Proteins c-jun / metabolism
  • Psoriasis / drug therapy
  • Psoriasis / metabolism*
  • RNA, Messenger / genetics
  • Skin / metabolism*
  • Transcription Factor AP-1 / drug effects
  • Transcription Factor AP-1 / metabolism*

Substances

  • DNA-Binding Proteins
  • Dermatologic Agents
  • Proto-Oncogene Proteins c-fos
  • Proto-Oncogene Proteins c-jun
  • RNA, Messenger
  • Transcription Factor AP-1
  • calcipotriene
  • Calcitriol